RNAC FY 2020 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+148.6% YoY

Gross Profit

$17M100.0% margin

Operating Income

-$57M-342.4% margin

Net Income

-$69M-415.0% margin

EPS (Diluted)

$-20.42

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$34M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$165M

Total Liabilities

$183M

Stockholders' Equity

-$18M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$7M	+148.6%
Gross Profit	$17M	$7M	+148.6%
Operating Income	-$57M	-$52M	-8.3%
Net Income	-$69M	-$55M	-24.4%